Advocacy intelligence hub — real-time data for patient organizations
Octapharma — PHASE4
Hoffmann-La Roche — PHASE1, PHASE2
St. Jude Children's Research Hospital
Novo Nordisk A/S — PHASE1
Northwell Health — PHASE2
Pfizer
Novo Nordisk A/S — PHASE1
Novo Nordisk A/S
Runhui WU — PHASE4
Swedish Orphan Biovitrum — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
ALTUVIIIO
(ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC-VWF-XTEN FUSION PROTEIN-EHTL)Orphan drugBioverativ Therapeutics Inc.
ROCTAVIAN
(VALOCTOCOGENE ROXAPARVOVEC-RVOX)Orphan drugBioMarin Pharmaceutical Inc.
Hemlibra
(EMICIZUMAB)Orphan drugGenentech, Inc.
Alhemo
(CONCIZUMAB)Orphan drugstandardNovo Nordisk
HYMPAVZI
(MARSTACIMAB-HNCQ)Orphan drugPfizer Laboratories Div Pfizer Inc
Humate-P
(Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized)Orphan drugstandardCSL Behring
Qfitlia
(FITUSIRAN)Orphan drugstandardGenzyme Corporation
Perioperative Management for Port Catheter Procedures in Pediatric Patients with Severe Hemophilia and Inhibitors.
The objective of this systematic study was to assess the perioperative management and outcome of surgery in pediatric patients with hemophilia A/B and inhibitors compared to nonhemophilic pediatric pa...
Acquired Hemophilia A Following Omalizumab Treatment in a Patient With Chronic Spontaneous Urticaria.
Acquired Hemophilia A Following Omalizumab Treatment in a Patient With Chronic Spontaneous Urticaria.
Factor VIII Pharmacokinetics in Mexican Patients with Hemophilia A.
Treatment of patients with severe hemophilia A requires the replacement of deficient factor VIII. To reach the international standards of care, an optimal dose of factor VIII should be administered ba...
[Acquired hemophilia A].
[Acquired hemophilia A].
Immunogenicity of Gene and Cell Therapies.
Gene and cell therapies have been gaining popularity with market approvals by the US Food and Drug Administration, European Medicines Agency, and other regulatory bodies. Adeno-associated viral vector...
Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.
Bispecific antibodies are used to treat various conditions, with notable results in hemophilia A, a rare bleeding disorder characterized by reduced or absent activity of the coagulation factor VIII (F...
Rubén Cuesta-Barriuso, PhD
Universidad de Oviedo
Savita Rangarajan, FRCP FRCPath
Basingstoke & North Hampshire Hospital
Elena Santagostino, MD
Sobi Investigational Site
📍 Sofia
Marc TROSSAERT, Dr
Nantes University Hospital
Brigitte Tardy, MD
Centre Hospitalier Universitaire de Saint Etienne
Peter A Kouides, MD, M.D
Mary M. Gooley Hemophilia Center
📍 ROCHESTER, NY